- Home
- RIGL vs EBS Comparison
RIGL vs EBS Comparison
Compare RIGL & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- EBS
- Stock Information
- Founded
- RIGL 1996
- EBS 1998
- Country
- RIGL United States
- EBS United States
- Employees
- RIGL N/A
- EBS N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- RIGL Health Care
- EBS Health Care
- Exchange
- RIGL Nasdaq
- EBS Nasdaq
- Market Cap
- RIGL 537.6M
- EBS 529.9M
- IPO Year
- RIGL 2000
- EBS 2006
- Fundamental
- Price
- RIGL $41.64
- EBS $10.17
- Analyst Decision
- RIGL Buy
- EBS Strong Buy
- Analyst Count
- RIGL 6
- EBS 2
- Target Price
- RIGL $39.83
- EBS $13.50
- AVG Volume (30 Days)
- RIGL 652.5K
- EBS 1.5M
- Earning Date
- RIGL 11-04-2025
- EBS 10-29-2025
- Dividend Yield
- RIGL N/A
- EBS N/A
- EPS Growth
- RIGL 2698.26
- EBS N/A
- EPS
- RIGL 6.20
- EBS 1.35
- Revenue
- RIGL $282,076,000.00
- EBS $788,900,000.00
- Revenue This Year
- RIGL $59.93
- EBS N/A
- Revenue Next Year
- RIGL N/A
- EBS $15.42
- P/E Ratio
- RIGL $6.77
- EBS $7.48
- Revenue Growth
- RIGL 79.13
- EBS N/A
- 52 Week Low
- RIGL $14.63
- EBS $4.02
- 52 Week High
- RIGL $43.72
- EBS $13.41
- Technical
- Relative Strength Index (RSI)
- RIGL 69.25
- EBS 50.26
- Support Level
- RIGL $34.00
- EBS $9.93
- Resistance Level
- RIGL $39.56
- EBS $11.02
- Average True Range (ATR)
- RIGL 2.36
- EBS 0.83
- MACD
- RIGL 1.09
- EBS -0.11
- Stochastic Oscillator
- RIGL 91.70
- EBS 21.91
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.